Form 4: Dyne Therapeutics Director Granted 35,000 Stock Options as Part of Compensation

Dyne Therapeutics, Inc. Director Carlo Incerti was granted 35,000 stock options with an exercise price of $11.96, vesting in 2026.

Summary

• Carlo Incerti, a Director of Dyne Therapeutics, Inc. (DYN), was granted 35,000 stock options.
• The transaction date for this grant was May 30, 2025.
• The exercise price for these options is $11.96 per share.
• The options are scheduled to vest in full on the earlier of May 30, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
• The options have an expiration date of May 29, 2035.
• Following this transaction, Carlo Incerti beneficially owns 35,000 derivative securities directly.
• A Limited Power of Attorney was executed by Carlo Incerti on June 3, 2025, authorizing specific individuals to handle his Section 16 reporting obligations for Dyne Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for the individual, aligning their interests with the company's long-term performance. For the company, it represents a standard compensation practice that incentivizes leadership, generally viewed as neutral to slightly positive.

Positives

• The grant of 35,000 stock options to Director Carlo Incerti aligns his interests with those of shareholders, as the options gain value if the company's stock price increases.
• The options have a long expiration date of May 29, 2035, providing a significant window for potential value realization.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Dyne Therapeutics, Inc.'s common stock. If the stock price does not exceed the exercise price of $11.96, the options may expire worthless.

Future Outlook

The stock options granted to Director Carlo Incerti are scheduled to vest in full on the earlier of May 30, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent upon his continued service.

Industry Context

The grant of stock options is a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation packages across the biotechnology sector, similar to practices at companies like Moderna (MRNA) or BioNTech (BNTX), which frequently use equity to attract and retain talent.
• The vesting schedule, tied to a specific date or the annual meeting, is a typical structure for director equity awards, ensuring continued commitment to the company's governance and strategic direction.

Corporate Governance

Related Party Transactions

• The grant of stock options to Carlo Incerti, a Director of Dyne Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with shareholder value creation, as the options' value increases with the company's stock price. However, it also represents potential future dilution if options are exercised.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The stock options will vest on the earlier of May 30, 2026, or the date of Dyne Therapeutics' 2026 Annual Meeting of Stockholders, subject to Carlo Incerti's continued service.

Key Dates

Keywords

Dyne Therapeutics, DYN, Stock Options, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Carlo Incerti, Biotechnology